Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 38.42M | 39.26M | 0.00 | 0.00 | 0.00 |
Gross Profit | -672.94M | 24.24M | -475.64M | -66.27M | 0.00 |
EBITDA | -916.54M | -45.07M | -2.39B | -2.23B | -335.04M |
Net Income | -903.43M | -138.54M | -2.45B | -6.02B | -915.87M |
Balance Sheet | |||||
Total Assets | 812.74M | 2.10B | 4.69B | 5.35B | 1.19B |
Cash, Cash Equivalents and Short-Term Investments | 427.53M | 752.97M | 1.64B | 2.87B | 806.51M |
Total Debt | 89.64M | 334.45M | 354.37M | 67.92M | 22.32M |
Total Liabilities | 2.45B | 2.83B | 5.36B | 4.13B | 2.17B |
Stockholders Equity | -1.64B | -732.83M | -668.14M | 1.22B | -982.74M |
Cash Flow | |||||
Free Cash Flow | -290.11M | -737.05M | -1.80B | -998.07M | 363.13M |
Operating Cash Flow | -288.49M | -727.88M | -1.69B | -917.75M | 476.93M |
Investing Cash Flow | 3.17M | -6.16M | -37.51M | 112.12M | -394.12M |
Financing Cash Flow | -51.50M | -142.41M | 483.14M | 3.06B | 316.85M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$15.71B | 5.67 | -7.43% | 4.09% | 11.60% | -21.06% | |
54 Neutral | HK$389.12M | ― | ― | -1.73% | -689.53% | ||
52 Neutral | HK$659.39M | ― | -266.90% | ― | ― | 31.23% | |
47 Neutral | HK$640.84M | ― | -32.59% | ― | -79.65% | 37.50% | |
46 Neutral | HK$3.81B | ― | -69.97% | ― | ― | 3.30% | |
45 Neutral | HK$7.01B | 289.31 | 2.28% | ― | -57.55% | -87.49% | |
36 Underperform | HK$660.43M | ― | -41.20% | ― | ― | 85.23% |
Clover Biopharmaceuticals Ltd. announced changes to its board of directors and committee memberships, effective July 1, 2025. Dr. Donna Marie Ambrosino and Mr. Xiang Liao have been appointed as members of the Nomination Committee, reflecting the company’s ongoing efforts to strengthen its governance structure.
Clover Biopharmaceuticals Ltd. has established a Nomination Committee to oversee director appointments, ensuring diversity and independence within its board. This move is part of the company’s governance strategy to enhance operational efficiency and maintain transparency, potentially strengthening its industry position and stakeholder confidence.
Clover Biopharmaceuticals Ltd. announced the results of its Annual General Meeting held on June 19, 2025, where all proposed resolutions were passed unanimously. The meeting also marked the retirement of a non-executive director, and the re-election of other directors, along with the appointment of a new auditor, highlighting the company’s stable governance and strategic planning.
Clover Biopharmaceuticals Ltd. has initiated a Phase I clinical trial for its new respiratory combination vaccine candidates, SCB-1022 and SCB-1033, which target RSV, hMPV, and PIV3. This trial follows promising results from a previous study comparing Clover’s RSV PreF vaccine candidate to GSK’s AREXVY, indicating a strong immunogenicity and tolerability profile. The ongoing trial will enroll up to 192 older adults to assess the safety, reactogenicity, and immunogenicity of these new vaccine candidates, potentially strengthening Clover’s position in the vaccine market.
Clover Biopharmaceuticals Ltd. announced the termination of its exclusive agreement with Adimmune Corporation to distribute AdimFlu-S (QIS) in mainland China, effective June 30, 2025, due to material changes in market conditions. The company believes this termination will not adversely impact its operations and remains focused on advancing its RSV vaccine candidate SCB-1019, which is part of its strategic objectives.
Clover Biopharmaceuticals Ltd. announced that it has received an arbitration request from Gavi, seeking repayment of $224 million in advance payment amounts. Clover believes the claim is without merit and intends to defend itself vigorously, while continuing its development of the RSV vaccine candidate SCB-1019.
Clover Biopharmaceuticals Ltd. has announced its upcoming annual general meeting scheduled for June 19, 2025, in Chengdu, China. Key agenda items include the adoption of financial statements for 2024, re-election of directors, and the appointment of auditors. Additionally, the meeting will address resolutions to authorize the board to manage share capital, which may impact the company’s future financial strategies and shareholder value.